Purification of CD34+ cells in myasthenia gravis patient’s peripheral blood stem cells using the CliniMACS cell separation system

  • Nguyen Thi Duyen 108 Military Central Hospital,National Children Hospital
  • Mai Van Vien 108 Military Central Hospital
  • Ly Tuan Khai 108 Military Central Hospital
  • Le Hai Son 108 Military Central Hospital
  • Nguyen Thi Minh Phuong 108 Military Central Hospital
  • Le Thi Thu Nga 108 Military Central Hospital
  • Bui Tien Sy 108 Military Central Hospital
  • Phan Quoc Hoan 108 Military Central Hospital
  • Ngo Tien Tuan 108 Military Central Hospital
  • Ho Xuan Truong 108 Military Central Hospital
  • Pham Van Hieu 108 Military Central Hospital
  • Tran Thi Huyen Trang 108 Military Central Hospital
  • Dao Thi Hong Nga 108 Military Central Hospital
  • Nguyen Bao Ngoc National Children Hospital
  • Le Duc Minh National Children Hospital
  • Nguyen Thanh Binh National Children Hospital,Hanoi Medical University

Main Article Content

Keywords

HSCT, PBSC, CD34 selection, myasthenia gravis, CliniMACS

Abstract

Autologous hematopoietic stem cell transplantation therapy has been widely used in recent decades for the treatment of hematological diseases, cancer, and autoimmune diseases. In autoimmune diseases, self-activated T lymphocytes and B lymphocytes secreting antibodies against host antigens are considered to be central in the pathogenesis of the disease. Autologous stem cell products that eliminates these pathological cells could be a lifesaver for patients with autoimmune diseases who are resistant to conventional therapy, in order to restore a healthy immune system, achieve long-term remission and limited recurrence. The aims of this study was to complete and evaluate the results of the CD34 positive stem cells purification procedure from a myasthenia gravis patient’s mobilized peripheral blood stem cells, for the purpose of autologous hematopoietic stem cell transplantation for Myasthenia gravis as well as other autoimmune diseases in Vietnam. We have completed the purification procedure of CD34-positive stem cells from mobilized peripheral blood stem cells of patient with myasthenia gravis using CliniMACS system with results of removing 99.99% of T lymphocytes; 99.81% of B lymphocytes; 99.99% of NK cells, while CD34+ recovery performance was 64.05% with CD34+ cell survival rate of over 99%, no bacterial contamination, ensuring quality assurance of stem cell product for transplantation.

Article Details

References

1. Kaminski HJ, Kusner LL (2018) Myasthenia gravis and related disorders. Springer International Publishing. doi:10.1007/978-3-319-73585-6.
2. Díaz-Manera J, Rojas García R, Illa I (2012) Treatment strategies for myasthenia gravis: An update. Expert Opin Pharmacother 13(13): 1873-1883. doi:10.1517/14656566.2012.705831.
3. Ng SA, Sullivan KM (2019) Application of stem cell transplantation in autoimmune diseases. Curr Opin Hematol 26(6): 392-398. doi:10.1097/MOH.000000 0000000531
4. Koneczny I, Herbst R (2019) Myasthenia gravis: Pathogenic effects of autoantibodies on neuromuscular architecture. Cells 8(7): 671. doi:10. 3390/cells8070671
5. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases - PubMed. Accessed July 2, 2021. https://pubmed.ncbi.nlm.nih.gov/29296926.
6. Gratwohl A, Baldomero H, Aljurf M et al (2010) Hematopoietic stem cell transplantation: A global perspective. JAMA 303(16): 1617-1624. doi:10. 1001/jama.2010.491.
7. Wahren-Herlenius M, Dörner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet Lond Engl. 382(9894): 819-831. doi:10.1016/S0140-6736(13)60954-X.
8. Busca A, Aversa F (2017) In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation. Expert Opin Biol Ther 17(11): 1401-1415. doi:10.1080/14712598.2017.1369949.
9. Després D, Flohr T, Uppenkamp M et al (2000) CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device. J Hematother Stem Cell Res 9(4): 557-564. doi:10.1089/152581600419242.
10. Bryant A, Atkins H, Pringle CE, et al (2016) Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol 73(6): 652. doi:10.1001/jamaneurol. 2016.0113.
11. Håkansson I, Sandstedt A, Lundin F et al (2017) Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis – a case report. Neuromuscul Disord 27(1): 90-93. doi: 10.1016/j.nmd.2016.09.020.
12. Strober J, Cowan MJ, Horn BN (2009) Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 66(5): 659-661. doi:10.1001/ archneurol.2009.28.
13. Imai Y, Chou T, Tobinai K et al (2005) Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: Purging efficacy, hematopoietic reconstitution in non-Hodgkin’s lymphoma (NHL): results of Japanese phase II study. Bone Marrow Transplant 35(5): 479-487. doi:10.1038/sj.bmt.1704819.
14. Leong CF, Habsah A, Teh HS, Goh KY, Fadilah SA, Cheong SK (2008) Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience. Malays J Pathol 30(1): 31-36. PMID: 19108409.
15. Lopez M, Beaujean F (1999) Positive selection of autologous peripheral blood stem cells. Baillieres Best Pract Res Clin Haematol. 1999 Mar-Jun;12(1-2):71-86. doi: 10.1053/beha.1999.0008.

Article Sidebar

PDF
Published
Dec 13, 2021
DOI: https://doi.org/10.52389/ydls.v16iTA.1123
Issue
Volume 16 - December 2021
Section
Articles
How to Cite
DuyenN. T., VienM. V., KhaiL. T., SonL. H., PhuongN. T. M., NgaL. T. T., SyB. T., HoanP. Q., TuanN. T., TruongH. X., HieuP. V., TrangT. T. H., NgaD. T. H., NgocN. B., MinhL. D., & Binh N. T. (2021). Purification of CD34+ cells in myasthenia gravis patient’s peripheral blood stem cells using the CliniMACS cell separation system. Tạp Chí Y Dược lâm sàng 108, 16(TA). https://doi.org/10.52389/ydls.v16iTA.1123